Login / Signup

TP53 Signature Can Predict Pathological Response From Neoadjuvant Chemotherapy and Is a Prognostic Factor in Patients With Residual Disease.

Shin TakahashiKeiju SasakiChikashi Ishioka
Published in: Breast cancer : basic and clinical research (2023)
mutant signature allows for the identification of subgroups with truly poor prognosis.
Keyphrases
  • poor prognosis
  • neoadjuvant chemotherapy
  • prognostic factors
  • long non coding rna
  • locally advanced
  • lymph node
  • sentinel lymph node
  • rectal cancer
  • radiation therapy
  • early stage
  • wild type
  • bioinformatics analysis